|By PR Newswire||
|April 25, 2014 08:01 AM EDT||
NEW YORK, April 25, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Wal-Mart Stores Inc. (NYSE: WMT), Walgreen Co (NYSE: WAG), Walt Disney Co (NYSE: DIS), eBay Inc (NASDAQ: EBAY) and Michael Kors Holdings Ltd. (NYSE: KORS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1617-100free.
Wal-Mart Stores Inc. Analyst Notes
On April 22, 2014, Wal-Mart Stores Inc. (Walmart) reported that as Mother's Day is drawing close, the Company is expanding its Empowering Women Together product offering of unique and meaningful gifts that will celebrate moms everywhere while supporting small women-owned businesses from around the world. The Company stated that it is increasing the availability of products created by small women-owned businesses beyond its current online platform into more than 2,600 stores nationwide. MiKaela Wardlaw Lemmon, Senior Director of Women's Economic Empowerment at Walmart, commented, "Empowering Women Together began as an online platform one year ago, and this spring we are bringing select products in-store. By offering these products in-store, several small women-owned businesses will now have access to more than an estimated 100 million shoppers." Walmart, in association with Full Circle Exchange, an innovative social enterprise brand, identified five suppliers to bring these new products into Walmart stores this spring. The full analyst notes on Walmart are available to download free of charge at:
Walgreen Co Analyst Notes
On April 21, 2014, Walgreen Co. (Walgreens) announced that it is expanding the scope of its travel health services to include immunization and consultation services, in support of nearly 60 million annual planned trips by U.S. residents outside the country. The Company informed that travel immunizations are widely available at more than 5,000 Walgreens stores in 41 states. Jack Cantlin, Walgreens Divisional Vice President, Retail Clinical Services, commented, "In addition to immunizations, there's a lot of pertinent health information people need when traveling to other parts of the world. By expanding our travel health services and spending more time with patients, Walgreens can serve as a convenient resource for all international travel needs." The travel health consultations provided by Walgreen include travel itinerary review and recommendations on immunizations, prescriptions refills and over-the-counter medications. The full analyst notes on Walgreens are available to download free of charge at:
Walt Disney Co Analyst Notes
On April 22, 2014, the shares of Walt Disney Co. (Disney) gained 0.43% to close at $79.45. During the session, the Company's shares opened at $79.22 and fluctuated in the range of $79.21 - $79.89. A total of 5.88 million shares changed hands during the session. Over the past 12 months, the shares of the Company increased 26.94%, outperforming the NYSE Composite, which increased 16.30% during the same period. According to a Bloomberg report dated April 21, 2014, Disney's superhero film- 'Captain America-The Winter Soldier' was No. 1 for a third straight weekend in the U.S. and Canada, with sales of $26.6 million. The full analyst notes on Disney are available to download free of charge at:
eBay Inc Analyst Notes
On April 22, 2014, eBay Inc.'s (eBay) stock gained 0.98%, closing the day at $55.47, in line with the broader market index NASDAQ Composite which increased 0.97% during the same period. During the session, the Company's shares opened at $54.88 and fluctuated in the range of $54.56 - $55.62. A total of 7.46 million shares of eBay were traded during the session. Over the past 12 months, the shares of the Company increased 5.68%, as compared to the NASDAQ Composite, which increased 27.29% during the same period. The full analyst notes on eBay are available to download free of charge at:
Michael Kors Holdings Ltd. Analyst Notes
On April 15, 2014, Michael Kors Holdings Ltd. (Michael Kors) and Luxottica Group (Luxottica) jointly announced a new and exclusive eyewear license agreement for the Michael Kors Collection and Michael Kors eyewear. The Company stated that the first collection produced with Luxottica will launch in January 2015. Michael Kors stated that the 10-year partnership agreement with Luxottica will allow it to further expand its eyewear business globally. Commenting on the agreement, John D. Idol, CEO of Michael Kors, said, "Luxottica is the industry leader in eyewear through their commitment to design and quality which makes them the perfect partner for our luxury brand. Our eyewear business is an important component of the overall growth strategy as we continue our expansion around the world." The full analyst notes on Michael Kors are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review